Ginsenoside F1

Research use only, not for human use.

Ginsenoside F1,an enzymatically modified derivative of ginsenoside Rg1, protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression.

Ginsenoside F1,an enzymatically modified derivative of ginsenoside Rg1, protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression. Ginsenoside F1 exhibited competitive inhibition of the activity of CYP3A4 with Ki values of 57.7 ± 9.6 μM and 67.8 ± 16.2 μM, respectively. Ginsenoside F1 exhibited a weaker inhibition of the activity of CYP2D6.

Ginsenoside F1 has been shown to flaunt anticancer, anti-aging, and antioxidant effects and has demonstrated competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity. The cell viabilities are 68% at the highest concentration of ginsenoside F1 (200 μM) in MTT assays.

ApoE-/- mice are fed a high fat diet and orally treated with Ginsenoside F1 (50 mg/kg/day) for 8 weeks.Ginsenoside F1 treated mice significantly reduce the lesion size compared with model group mice.

——

Metabolic Enzyme/Protease

P450

CYP3A4

Other Indications

——

53963-43-2

638.88

C36H62O9

>98% (HPLC)

Soluble in Pyridine, Methanol, Ethanol, etc.

CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C

——

(-20℃)

With Ice Pack

≥ 2 years